June 17 (Reuters) - Ventyx Biosciences Inc VTYX.O:
VENTYX BIOSCIENCES ANNOUNCES POSITIVE TOP-LINE DATA FROM ITS PHASE 2A SAFETY AND BIOMARKER TRIAL EVALUATING VTX3232 IN PATIENTS WITH EARLY-STAGE PARKINSON’S DISEASE
VENTYX BIOSCIENCES INC - VTX3232 STUDY MEETS PRIMARY GOAL OF SAFETY AND TOLERABILITY
VENTYX BIOSCIENCES INC - VTX3232 SHOWS SIGNIFICANT REDUCTIONS IN NLRP3-RELATED BIOMARKERS
VENTYX BIOSCIENCES INC - VTX3232 PHASE 2 TRIAL IN OBESITY AND CARDIOMETABOLIC RISK FACTORS RESULTS EXPECTED H2 2025
Source text: ID:nGNX3SC0t2
Further company coverage: VTYX.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.